Navigation Links
Nobles Medical Technologies II Receives US Patent for “Suturing and Method” for its NobleStitch Technology
Date:9/13/2013

Fountain Valley, California (PRWEB) September 13, 2013

Nobles Medical Technologies II today announced that it has received another US Patent for its NobleStitch Technology. The patent is for the Device and Method of our suturing technology. This patent shows the broad coverage of our method as used throughout the entire body and all biological tissue.

Prof. Dr. Anthony Nobles, CEO of NMT2 and co-inventor on the issued patent commented, “Intellectual property is one of the most valuable assets we have, in the medical device industry patents represent one of the greatest measurements of the value of the company. This patent carry’s broad coverage for all of our applications for our technology and is a critical piece of our portfolio.”

Ben Brosch, President of NMT2 and co-inventor on the issued patent commented, “We strive to protect our inventions with strong patents that help us protect our technology. We continuously file new patents and have grown an extensive portfolio of patents and trademarks adding value to our company and its shareholders”.

About Patent Foramen Ovale (PFO)
A PFO is a tunnel that exists between the left and right atrium of the heart. The tunnel, which is part of the normal fetal anatomy, should close shortly after birth. In 27% of the population the tunnel never closes. This tunnel can then allow clots and other chemicals to pass from the right to the left side of the heart freely bypassing the filter of the lungs. These clots and chemicals can cause strokes and other conditions such as severe migraines.

About the NobleStitch EL System
Nobles Medical Technologies II's NobleStitch EL is a catheter based system that allows a physician to place a suture in the PFO tunnel in the heart through a percutaneous puncture in the leg, in many cases under a local anesthetic in a catheter lab rather than an operating room. This eliminates the need for open-heart surgery or placement of a large metallic implant in the heart. The NobleStitch is not a “device” or mechanical implant it only places a simple polypropylene suture in the heart. By closing the hole or PFO, the therapy will reduce or eliminate the shunting from the right to the left side of the heart allowing the lungs to filter the clots and other chemicals from making it to the brain, potentially halting strokes and severe migraines and enabling patients to live a higher-quality life.

About Nobles Medical Technologies II
Nobles Medical Technologies II is a global structural heart company devoted to improving life through the development of its products and technologies. Nobles Medical Technologies II is focused on suture based solutions for the septum. The NobleStitch is available in Europe and is undergoing and IRB study for specific indication in the US. The NobleStitch has CE mark for “Cardiovascular suturing and PFO closure” and US FDA 510k clearance for “vascular suturing”

Visit Nobles Medical Technologies II http://www.noblesmedicaltechnology.com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11118545.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Nobles Medical Technologies II's NobleStitch EL Receives Strong Reviews from Physicians at Congenital & Structural Interventions Congress (CSI) in Frankfurt
2. Nobles Medical Technologies II's NobleStitch EL begins Sales in Europe
3. Boston Medical Center Wins the $100,000 Drucker Award for Nonprofit Innovation
4. North Shore Eye Care Adds Ophthalmologists Lawrence Buono, MD Christine Speer-Buono, MD To Medical Staff
5. Diet Doc Medical Weight Loss Plans Now Offers Body Fat Burning Best Diet Pills Without Having to Travel to a Local Weight Loss Clinic
6. InventHelp® Client Develops Better Medical Valve (DVR-579)
7. 1 Focus Medical Software Offering Promotional Discount for Dragon Medical Practice Edition 2
8. Diet Doc Announces Improved Medical Diet Plans That Help Patients Avoid Excess Weight Gain, Now Found to Possibly be Caused by Antidepressant Medication
9. InnerVision Medical Technologies Develops Ultrasound Device to Image Morbidly Obese
10. Discount Medical Supplies Launches a Mobile Version to Help Customers Place Orders on the Go
11. Medical Device Manufacturing in China Industry Research Report – Now Available from IBISWorld
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology: